Charles Schwab
EIGR

Charles Schwab’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Charles Schwab’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,115
Closed -$7.51K – 3535
2023
Q4 		$7.51K Hold
1,115
– – ﹤0.01% 3534
2023
Q3 		$10.2K Hold
1,115
– – ﹤0.01% 3564
2023
Q2 		$23.5K Sell
1,115
-2,080
-65% -$64.1K ﹤0.01% 3540
2023
Q1 		$86K Sell
3,195
-549
-15% -$25.5K ﹤0.01% 3274
2022
Q4 		$133K Buy
3,744
+126
+3% +$15.1K ﹤0.01% 3235
2022
Q3 		$818K Buy
3,618
+68
+2% +$16.7K ﹤0.01% 2851
2022
Q2 		$671K Buy
3,550
+593
+20% +$120K ﹤0.01% 2949
2022
Q1 		$737K Buy
2,957
+65
+2% +$10.3K ﹤0.01% 2971
2021
Q4 		$451K Hold
2,892
– – ﹤0.01% 3181
2021
Q3 		$580K Buy
2,892
+124
+4% +$29.5K ﹤0.01% 3095
2021
Q2 		$708K Buy
2,768
+204
+8% +$50.9K ﹤0.01% 3053
2021
Q1 		$681K Buy
2,564
+91
+4% +$28.7K ﹤0.01% 2975
2020
Q4 		$912K Buy
2,473
+227
+10% +$65.1K ﹤0.01% 2806
2020
Q3 		$549K Buy
2,246
+189
+9% +$58.8K ﹤0.01% 2849
2020
Q2 		$593K Buy
2,057
+61
+3% +$18K ﹤0.01% 2769
2020
Q1 		$408K Sell
1,996
-31
-2% -$9.88K ﹤0.01% 2778
2019
Q4 		$906K Buy
2,027
+248
+14% +$88K ﹤0.01% 2628
2019
Q3 		$547K Hold
1,779
– – ﹤0.01% 2763
2019
Q2 		$566K Buy
+1,779
New +$616K ﹤0.01% 2751

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Charles Schwab's EIGR Position: Q1 2024 in Review

Charles Schwab sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 1,115 shares — an estimated $7.51K sold.

Charles Schwab first reported a position in EIGR in Q2 2019 and held it in 19 quarters. The position peaked at $912K in Q4 2020. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • Charles Schwab reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Charles Schwab sold 1,115 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $7.51K.
  • Charles Schwab first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2019 and held it in 19 quarters.
  • Charles Schwab's Eiger BioPharmaceuticals, Inc. position peaked at $912K in Q4 2020.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.